NCT04999605View on ClinicalTrials.gov

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

June 10, 2022

Study Completion Date

June 10, 2022

Conditions
Ovarian NeoplasmsRecurrent Ovarian CarcinomaRelapsed Ovarian CancerOvarian Cancer
Interventions
DRUG

AK112 low dose

AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor

DRUG

AK112 medium dose

AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor

DRUG

AK112 high dose

AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor

Trial Locations (1)

100000

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT04999605 - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter